BBA
CRDL

Baader Bank Aktiengesellschaft’s Cardiol Therapeutics CRDL Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,932
Closed -$10.2K – 443
2026
Q1 		$10.2K Buy
+15,932
New +$16.4K ﹤0.01% 406
2025
Q4 		– Sell
-13,825
Closed -$6.66K – 484
2025
Q3 		$6.66K Buy
+13,825
New +$16.8K ﹤0.01% 476
2024
Q3 		– Sell
-29,028
Closed -$34.4K – 468
2024
Q2 		$34.4K Buy
+29,028
New +$61.6K ﹤0.01% 381

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Baader Bank Aktiengesellschaft's CRDL Position: Q2 2026 in Review

Baader Bank Aktiengesellschaft sold out of Cardiol Therapeutics (CRDL) in Q2 2026, closing a stake of 15,932 shares — an estimated $10.2K sold.

Baader Bank Aktiengesellschaft first reported a position in CRDL in Q2 2024 and held it in 3 quarters. The position peaked at $34.4K in Q2 2024. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Baader Bank Aktiengesellschaft reported no remaining Cardiol Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 15,932 Cardiol Therapeutics shares in Q2 2026, an estimated $10.2K.
  • Baader Bank Aktiengesellschaft first reported a position in Cardiol Therapeutics in Q2 2024 and held it in 3 quarters.
  • Baader Bank Aktiengesellschaft's Cardiol Therapeutics position peaked at $34.4K in Q2 2024.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q2 2026, filed 23 Jul 2026.